One titrimetric and two spectrophotometric methods are described for the determination of ketotifen fumarate (KTF) in bulk drug and in tablets using cerium(IV) as the oxidimetric agent. In titrimetry (method A), the drug was treated with a measured excess of cerium(IV) in H2SO4 medium and after a standing time of 10 min, the surplus oxidant was determined by back titration with iron(II). The spectrophotometric procedures involve addition of a known excess of cerium(IV) to KTF in acid medium followed by the determination of unreacted oxidant by reacting with either p-dimethyl amino benzaldehyde and measuring the resulting colour at 460?nm (method B) or o-dianisidine and subsequent measurement of the absorbance of coloured product at 470?nm (method C). Titrimetric assay is based on a 1?:?2 reaction stoichiometry between KTF and cerium(IV) and the method is applicable over 2–18?mg range. In spectrophotometry, regression analysis of Beer’s law plots showed a good correlation in 0.4–8.0 and 0.4–10.0?g?mL?1 KTF ranges for method B and method C, respectively, and the corresponding molar absorptivity coefficients are calculated to be and ?L?mol?1?cm?1. 1. Introduction Ketotifen fumarate (KTF) (Figure 1), chemically known as 4,9-dihydro-4-(1-methyl-4-piperidinylidene)-10H-benzo cyclohepta-[1,2-b] thiophen-10-one, which belongs to the group of cyclohepta thiophenones is an antiallergic drug with stabilizing action on mast cells, analogous to that of sodium cromoglycate, and anti-H1 effect [1]. Ketotifen is given orally as fumarate in the prophylactic management of asthma and is used in the treatment of allergic conditions such as rhinitis and conjunctivitis [2]. Ketotifen is a nonbronchodilator, antiallergic properties, and has a specific anti-H1 effect [3]. Figure 1: Structure of KTF. The drug is official in British Pharmacopoeia [4], which describes a potentiometric titration with perchloric acid in acetic anhydride-acetic acid medium. The therapeutic importance of the drug has prompted the development of a variety of techniques for its assay in pharmaceuticals and body fluids. In pharmaceuticals, it is quantified by high performance liquid chromatography [4–10], high performance thin layer chromatography [11], liquid chromatography with tandem mass spectrometry [12], capillary electrophoresis [13], spectrofluorimetry [14], direct differential pulse polarographic and adsorptive-stripping voltammetry [15], and UV spectrophotometry [16, 17]. Potentiometric titration methods employing polymeric membrane sensors were also developed, where the method involved
References
[1]
S. C. Sweetman, Martindale: The Complete Drug Reference, Pharmaceutical Press, London, UK, 2005.
[2]
F. Q. Alali, B. M. Tashtoush, and N. M. Naji, “Determination of ketotifen in human plasma by LC-MS,” Journal of Pharmaceutical and Biomedical Analysis, vol. 34, no. 1, pp. 87–94, 2004.
[3]
C. Dollery, Therapeutic Drugs, vol. 2 of pp. K25–K28, Churchill Livingstone, London, UK, 2nd edition, 1999.
[4]
M. A. Abounassif, H. A. El-Obeid, and E. A. Gadkariem, “Stability studies on some benzocycloheptane antihistaminic agents,” Journal of Pharmaceutical and Biomedical Analysis, vol. 36, no. 5, pp. 1011–1018, 2005.
[5]
G. L. Chen and H. Qu, “HPLC determination of ketotifen fumarate in compound metamizol sodium tablets,” Yaowu Fenxi Zazhi, vol. 23, no. 2, pp. 123–125, 2003.
[6]
I. P. Nnane, L. A. Damani, and A. J. Hutt, “Development and validation of stability indicating high-performance liquid chromatographic assays for ketotifen in aqueous and silicon oil formulations,” Chromatographia, vol. 48, no. 11-12, pp. 797–802, 1998.
[7]
S. S. Zarapkar, N. J. Bhounsule, and U. P. Halkar, “High performance liquid chromatographic determination of ketotifen I hydrogen fumarate in pharmaceuticals,” Indian Drugs, vol. 29, no. 8, pp. 365–366, 1992.
[8]
G. Hoogewijs and D. L. Massart, “Development of a standardized analysis strategy for basic drugs, using ion-pair extraction and high-performance liquid chromatography—III. Analysis of pharmaceutical dosage forms,” Journal of Pharmaceutical and Biomedical Analysis, vol. 2, no. 3-4, pp. 449–463, 1984.
[9]
S. Muralidharan, L. B. Han, Y. Ming, J. Lau, K. Sailishni, and S. Arumugam, “Simple and accurate estimation of ketotifen fumarate by RP-HPLC,” International Journal of Pharmaceutical, Chemical and Biological Sciences, vol. 2, no. 3, pp. 392–396, 2012.
[10]
M. H. Semreen, “Optimization and validation of HPLC method for the analysis of ketotifen fumarate in a pharmaceutical formulation,” Bulletin of Pharmaceutical Sciences, Assiut University, vol. 28, no. 2, pp. 291–296, 2005.
[11]
N. M. Sanghavi, K. A. Puranik, and M. M. Samarth, “Analysis of ketotifen fumarate by high performance thin layer chromatography,” Indian Drugs, vol. 32, no. 1, pp. 53–54, 1995.
[12]
N. Kyung-Don, T. Sung-Kwon, P. Ji-Sun et al., “Bioequivalence assessment of Fumatifen tablet to Zaditen tablet (ketotifen fumarate 1?mg) by liquid chromatography tandem mass spectrometry,” Journal of Pharmaceutical Investigation, vol. 42, no. 4, pp. 221–228, 2012.
[13]
M. Zhou, Y. Li, Y. Ma, W. Wang, J. Mi, and H. Chen, “Determination of ketotifen fumarate by capillary electrophoresis with tris(2,2′-bipyridyl) ruthenium(II) electrochemiluminescence detection,” Luminescence, vol. 26, no. 5, pp. 319–323, 2011.
[14]
C. S. P. Sastry and P. Y. Naidu, “Spectrofluorimetric estimation of ketotifen and terfenadine in pharmaceutical formulations,” Indian Drugs, vol. 35, no. 3, pp. 147–149, 1998.
[15]
P. M. Bersier, W. Szczepaniak, and M. Ren, “Direct differential pulse polarographic and adsorptive stripping voltammetric assay of ketotifen in tablets,” Archiv der Pharmazie, vol. 325, no. 5, pp. 253–259, 1992.
[16]
M. E. Mohamed and H. Y. Aboul-Enein, “Spectrophotometric and differential pulse polarographic methods of analysis for ketotifen hydrogen fumarate,” Drug Development and Industrial Pharmacy, vol. 12, no. 5, pp. 733–746, 1986.
[17]
W. Szczepaniak, T. Cychowska, and T. Przadka, “Spectrophotometric determination of ketotifen in pharmaceutical preparations after isolation on ion-exchanger.,” Acta poloniae pharmaceutica, vol. 49, no. 4, pp. 3–5, 1992.
[18]
H. Hopka?a and J. Drozd, “Ion-selective electrodes for the determination of antihistaminic drug ketotifen,” Chemia Analityczna, vol. 44, no. 3, pp. 603–609, 1999.
[19]
E. Y. Z. Frag, G. G. Mohamed, Gehad, M. M. Khalil, and M. A. Hwehy, “Potentiometric determination of ketotifen fumarate in pharmaceutical preparations and urine using carbon paste and PVC membrane selective electrodes,” International Journal of Analytical Chemistrypages, vol. 2011, Article ID 604741, 7 pages, 2011.
[20]
L. J. Li, W. Y. Gao, D. C. Hu, Z. Cai, and Y. Q. Li, “Electrochemiluminescence method for determination of ketotifen fumarate on glassy carbon electrode modified with platinum-multi-walled carbon nanotube modified electrode,” Fenxi Ceshi Xuebao, vol. 29, no. 11, pp. 1114–1120, 2010.
[21]
N. Fei and L. Jiuru, “Determination of ketotifen by using calcein as chemiluminescence reagent,” Analytica Chimica Acta, vol. 592, no. 2, pp. 168–172, 2007.
[22]
S. H. He, K. J. Tian, S. Q. Zhang, and W. Y. Yu, “Determination of ketotifen fumarate based on the chemiluminescence reaction of luminol with ferricyanide,” Fenxi Ceshi Xuebao, vol. 24, no. 2, pp. 98–99, 2005.
[23]
W. Ciesilski, R. Zakrzewski, and U. Z?obińska, “Coulometric titration of ketotifen in tablets,” Pharmazie, vol. 60, no. 3, pp. 237–238, 2005.
[24]
N. El-Kousy and L. I. Bebawy, “Determination of some antihistaminic drugs by atomic absorption spectrometry and colorimetric methods,” Journal of Pharmaceutical and Biomedical Analysis, vol. 20, no. 4, pp. 671–679, 1999.
[25]
C. S. P. Sastry and P. Y. Naidu, “Spectrophotometric estimation of ketotifen fumarate in pharmaceutical formulations,” Mikrochimica Acta, vol. 127, no. 3-4, pp. 219–223, 1997.
[26]
R. T. Sane, N. L. Chonkar, S. R. Surve, M. G. Gangrade, and V. V. Bapat, “Extractive colorimetrics estimation of (i) ticlopidine hydrochloride, (ii) buspirone hydrochloride, (iii) nefopam hydrochloride and (iv) ketotifen fumarate from pharmaceutical preparations,” Indian Drugs, vol. 30, no. 5, pp. 235–239, 1993.
[27]
M. Amanlou, M. H. Hoseinzadeh, H. Azizian, E. Souri, and H. Farsam, “Determination of Ketotifen fumarate in raw material and pharmaceutical products using ion-pair formation,” Analytical Letters, vol. 40, no. 16–18, pp. 3267–3279, 2007.
[28]
J. Vachek, “Photometric determination of Ketotifen,” Cesko-Slovenska Farmacie, vol. 36, no. 4, pp. 168–169, 1987.
[29]
O. Z. Devi, K. Basavaiah, H. D. Revanasiddappa, and K. B. Vinay, “Titrimetric and spectrophotometric assay of pantoprazole in pharmaceuticals using cerium(IV) sulphate as oxidimetric agent,” Journal of Analytical Chemistry, vol. 66, no. 5, pp. 490–495, 2011.
[30]
N. Rajendraprasad, K. Basavaiah, K. Tharpa, and K. B. Vinay, “Quantitative determination of olanzapine in tablets with visible spectrophotometry using cerium(IV)sulphate and based on redox and complexation Reactions,” Eurasian Journal of Analytical Chemistry, vol. 4, no. 2, pp. 191–203, 2009.
[31]
N. Rajendraprasad and K. Basavaiah, “Highly sensitive spectrophotometric determination of olanzapine using cerium(IV) and iron(II) complexes of 1,10-phenanthroline and 2,2'-bipyridyl,” Journal of Analytical Chemistry, vol. 65, no. 5, pp. 482–488, 2010.
[32]
K. Basavaiah, K. Tharpa, N. Rajendraprasad, S. G. Hiriyanna, and K. B. Vinay, “Sensitive cerimetric assay of olanzapine in pharmaceuticals,” Biomedical Journal, vol. 4, no. 2, pp. 159–175, 2009.
[33]
M. S. Raghu and K. Basavaiah, “Simple, sensitive and eco-friendly methods for the determination of methdilazine in tablets and syrup using cerium (IV),” Chemical Sciences Journal, vol. 2012, article CSJ-68, 2012.
[34]
A. I. Vogel, A Text-Book of Quantitative Inorganic Analysis, The English Language Book Edition Society, London, UK, 3rd edition, 1961.
[35]
B. R. DasGupta and D. A. Boroff, “Quantitative spectrophotometric determination of hydrogen peroxide with para-dimethylaminobenzaldehyde,” Analytical Chemistry, vol. 40, no. 13, pp. 2060–2062, 1968.
[36]
G. D. Christian, Text Book of Analytical Chemistry, John Wiley & Sons, Singapore, 2007.
[37]
“Validation of analytical procedures: text and methodology Q2 (R 1), complementary guideline on methodology,” in Proceedings of the International Conference on Hormonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline, London, UK, November 1996.
[38]
British Pharmacopoeia: Volume I and II, Her Majesty's Stationery Office, London, UK, 2009.